Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/03/24 | $170,000,000 | Series B |
Advent Life Sciences Forbion Capital Partners  Oxford Science Enterprises Syncona TCGX | undisclosed |
